OBJECTIVE To investigate the suitability and in vitro release performance of two antitumor active ingredients luteolin and matrine co-loaded with the composite carrier of iron fund organic frame material MIL-101(Fe) and graphene oxide (GO).
METHODS MIL-101 (Fe) and MIL-101(Fe)/GO composite carriers were prepared by the solvothermal method. The structures were characterized by SEM, XRD, BET and FT-IR. CCK-8 cell experiments were used to investigate the safety of the two carriers. The drug loading and release of luteolin and matrine in the composite carrier were determined by HPLC.
RESULTS The results of scanning electron microscopy showed that the MIL-101(Fe)/GO composite carrier was a polyhedral crystal structure composite system. The results of cell viability test showed that the two vectors did not inhibit mouse fibroblasts. The loading capacity of luteolin and matrine in MIL-101(Fe) were 14.1% and 10.63%, respectively; and the loading capacities of these two drugs in MIL-101(Fe)/GO were 20.74% and 14.1%, respectively. The results of in vitro release experiment showed that under the condition of pH=5, the complex carrier could release 23.92% luteolin and 32.07% matrine within 72 h, while under the condition of pH=7.4, the complex carrier could release 8.84% luteolin and 36.19% matrine within the same time.
CONCLUSIONS MIL-101(Fe)/GO composite carrier has higher drug loading capacity. As a pH-responsive composite carrier, it can effectively achieve the acidic pH response release of luteolin and slow release with matrine, providing a new idea for the design of anti-tumor drugs with multi-drug delivery and sustained release.
DownLoad: